- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03724227
Expanded Access for ACE-011
July 16, 2020 updated by: Celgene
This is an expanded access program (EAP) for eligible participants designed to provide access to ACE-011.
Study Overview
Status
No longer available
Conditions
Intervention / Treatment
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Summit, New Jersey, United States, 07901
- Celgene
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
-
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
October 26, 2018
First Submitted That Met QC Criteria
October 26, 2018
First Posted (Actual)
October 30, 2018
Study Record Updates
Last Update Posted (Actual)
July 17, 2020
Last Update Submitted That Met QC Criteria
July 16, 2020
Last Verified
October 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACE-011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndrome
-
University of California, DavisNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.CompletedPreviously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic SyndromeUnited States
-
Institut de Recherches Internationales ServierServier Bio-Innovation LLCRecruitingMyelodysplastic Syndromes (MDS) | Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)United States, France, United Kingdom, Spain, Australia, Germany, Brazil, Italy, Netherlands, Japan
-
TJ Biopharma Co., Ltd.Terminated
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
University Hospital, BrestRecruitingMyelodysplastic Syndromes | Myelodysplastic Syndrome With Isolated Del(5Q) | Myelodysplastic Syndrome With Del(5Q)France
-
Uma BorateActive, not recruitingTherapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic SyndromeUnited States
-
Cyclacel Pharmaceuticals, Inc.SuspendedLeukemia | Myelodysplastic Syndrome(MDS)United States
-
SCRI Development Innovations, LLCNovartis PharmaceuticalsTerminated
-
PersImmune, IncUniversity of California, San DiegoUnknown
Clinical Trials on ACE-011
-
CelgeneTerminatedBeta Thalassemia Intermedia | Beta Thalassemia MajorFrance, United Kingdom, Italy, Greece
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or AnemiaAnemia | Myelofibrosis | Myelodysplastic/Myeloproliferative NeoplasmUnited States
-
Mayo ClinicCompletedPulmonary Arterial HypertensionUnited States
-
Amsterdam UMC, location VUmcMerck Sharp & Dohme LLCRecruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAHNetherlands
-
CelgeneCompletedAnemia | Kidney Failure, ChronicBelgium, Spain, United Kingdom, Portugal, Germany
-
Merck Sharp & Dohme LLCTerminated
-
University of AlbertaAlberta Health services; Merck Canada Inc.Recruiting
-
Acceleron Pharma Inc. (a wholly owned subsidiary...CompletedOsteoporosisUnited States
-
Philipps University MarburgNot yet recruitingPAH | Congenital Heart Disease (CHD) | Eisenmenger Syndrome
-
Merck Sharp & Dohme LLCActive, not recruitingHypertension, PulmonaryUnited States, Belgium, Canada, France, Germany, Israel, Italy, Mexico, Poland, Spain, Sweden, United Kingdom